Schedule a seminar to learn about MaxCyte's cutting-edge electroporation technology
Schedule your live seminar with our team of experts
Let's meet! We would love to learn more about your projects and answer your questions during a live seminar with our commercial and technical experts. Choose between an online, hybrid or in person seminar, pre-built or customized just for your team.
We are looking forward to meeting you.
See available seminars
Genome Engineering
Description: Genome Engineering has tremendous potential as a therapeutic tool for treating human diseases. However, prolonged expression of the nuclease and gRNA from viral vectors in an in vivo context may cause unwanted off-target activity and immunogenicity. To overcome these safety issues, the MaxCyte system was developed for transient delivery of gene editors.
The MaxCyte platform can enable efficient & scalable genome engineering for knockouts, knockins, deletions, utilizing tools such as:
- CRISPR/Cas9
- Zinc Fingers
- Base Editors
- Prime Editors
- Novel Nucleases
Protein Production
Description: Our platforms can be leveraged for applications such as antibody production, cell line development, and recombinant protein production.
This includes:
- High Performance CHO & HEK293 transfection allows transient production in a manufacturing cell background
- Gram-Scale production sufficient for later stage development
- MaxCyte's technology shortens timeline of stable pool & cell line generation
- High performance produces faster cell recovery and allows strong selection pressure
Cell Therapy Production
MaxCyte's clinically validated, scalable electroporation system can be used in the pre-clinical and clinical scale engineering of cell therapy products. It's a flexible technology platform that can enable the next-generation non-viral CAR T therapies autologous, and allogeneic, off-the-shelf modalities with the potential for enhanced effectiveness for refractory cancer.
This includes applications such as:
- Using a mesothelin specific CARmRNA
- Enhancement of NK cell cytotoxicities against B cell malignancies using an antiCD19 CAR mRNA
- Transposon (Piggybac and Sleeping Beauty) based gene delivery for manufacture of CAR-T cells
- Gene editing of T cells for improving the efficacy of a TCR immunotherapy
Custom Seminar
Want a customized seminar for your lab? Happy to help!
Let's build a customized seminar just for your team.
We will tailor our content so we can answer all your questions.
